Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003289 · ClinicalTrials.gov registry record · Phase 1
UCN-01 in Treating Patients With Advanced Cancer
A Phase 1 study of Lymphoma and Leukemia, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00003289 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The trial reports 1 study location across 1 state.
The verdict
NCT00003289, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with advanced cancer that has not responded to previous treatment.
Conditions Studied
Interventions
- DRUG 7-hydroxystaurosporine
Study Locations (1)
Maryland
- Johns Hopkins Oncology Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003289
The ClinicalTrials.gov registry entry for NCT00003289 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which 7-hydroxystaurosporine is the first listed.
NCT00003289 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00003289 about?
NCT00003289 is a clinical study titled "UCN-01 in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with advanced cancer that has not responded to previous treatment.
What is the current status of trial NCT00003289?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-06.
What conditions does trial NCT00003289 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00003289?
The interventions under investigation include: 7-hydroxystaurosporine (DRUG).
Who is sponsoring clinical trial NCT00003289?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003289 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.